Register
  • Community
    • Physicians
    • Editors
    • Experts
    • Code of conduct
    • Blog
    • Terms of Use
    • Privacy Policy
    • Sitemap
  • Company
    • About
    • Publications
    • Press
    • Careers
  • Programs
    • Journal Club
    • Targeted Topic
    • Clinical Trial
    • Tumor Board
  • Contact Us
  • Sign in

Pediatric Oncology

Chemotherapy   

Questions discussed in this category


When using daratumumab in the setting of post-transplant red cell aplasia or post-transplant immune-mediated cytopenias, do you hold the drug for certain ANC parameters?
1 Answer available

What adjustments, if any, do you make to chemotherapy regimens for patients with chromosomal breakage disorders who develop malignancy?
Are there particular drugs you avoid or dose-adjustments that are recommended?
1 Answer available

In a patient with HR B ALL and severe pancreatitis due to peg-asparaginase, how do you assess the impact of peg discontinuation on risk of relapse?
For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?
2 Answers available
136301038810775


Papers discussed in this category


Cancers (Basel), 2022 Apr 14
Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders.

J Clin Oncol, 2020 Apr 10
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.

The Lancet. Oncology, 2017-09
Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.

Related Topics in Pediatric Oncology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Cancers
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2023 theMednet
All Rights Reserved.